ACTAVIA LIFE SCIENCES, INC.
RASP evidence brief
What we can confirm
- BioSniper Score:
- 2.7 / 10
- Market Cap:
- $386K
- Lead Asset:
- rasp-101 (Preclinical)
What it means
What to watch
Prepared research question
What matters most for RASP—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
$386K
Cash Runway
—
Lead Asset
rasp-101 (Preclinical)
Next Catalyst
—
Tracking 1 pipeline candidate for ACTAVIA LIFE SCIENCES, INC..
Run ACTAVIA LIFE SCIENCES, INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available ACTAVIA LIFE SCIENCES, INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 2 of 6 signals · derived from public data
Cash runway data unavailable
Financial health data unavailable
Lead: Preclinical
1 candidate
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Financials
Frequently asked questions
What is ACTAVIA LIFE SCIENCES, INC.'s lead drug candidate?
ACTAVIA LIFE SCIENCES, INC.'s most advanced tracked candidate is rasp-101 (Preclinical) for Acute myeloid leukemia (AML).
Where is ACTAVIA LIFE SCIENCES, INC. headquartered?
ACTAVIA LIFE SCIENCES, INC. (RASP) is headquartered in New York, NY, United States.
What therapeutic areas does ACTAVIA LIFE SCIENCES, INC. focus on?
ACTAVIA LIFE SCIENCES, INC. develops therapies across Oncology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.